Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Glaxo Smith Kline Intellectual Property (No 3) Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to examiner YU, DAVID TUYANG, who is the only examiner and the busiest examiner for the portfolio. Prosecution is currently limited to 1 distinct art unit.
The presence of 1 pending office action indicates a very specific focus for the company's current filings in this sector. Practitioners should monitor this examiner's tendencies within the art unit to resolve the pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577450 | USE OF OLIGONUCLEOTIDES FOR INDIVIDUALS WITH RENAL IMPAIRMENT | YU, DAVID TUYANG | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577450 | USE OF OLIGONUCLEOTIDES FOR INDIVIDUALS WITH RENAL IMPAIRMENT | YU, DAVID TUYANG | 1635 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGlaxo Smith Kline Intellectual Property (No 3) Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
David Tuyang Yu has the most, with 1 of Glaxo Smith Kline Intellectual Property (No 3) Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.